IL94939A - Transformed Analogs of Maginin Peptide and Their Use - Google Patents
Transformed Analogs of Maginin Peptide and Their UseInfo
- Publication number
- IL94939A IL94939A IL9493990A IL9493990A IL94939A IL 94939 A IL94939 A IL 94939A IL 9493990 A IL9493990 A IL 9493990A IL 9493990 A IL9493990 A IL 9493990A IL 94939 A IL94939 A IL 94939A
- Authority
- IL
- Israel
- Prior art keywords
- lys
- ala
- magainin
- peptide
- amino acid
- Prior art date
Links
- 238000006467 substitution reaction Methods 0.000 title claims abstract description 53
- 108060003100 Magainin Proteins 0.000 title description 10
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 139
- OFIZOVDANLLTQD-ZVNXOKPXSA-N magainin i Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 OFIZOVDANLLTQD-ZVNXOKPXSA-N 0.000 claims abstract description 86
- 108091005128 magainin I Proteins 0.000 claims abstract description 67
- 101500009721 Xenopus laevis Magainin-2 Proteins 0.000 claims abstract description 60
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 152
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 146
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 126
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 82
- MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 claims description 35
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 31
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 25
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 21
- -1 Ala Chemical compound 0.000 claims description 20
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 17
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 15
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 15
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims description 10
- 150000008574 D-amino acids Chemical group 0.000 claims description 10
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 7
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 108010030159 thrombin receptor peptide 14 Proteins 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000001150 spermicidal effect Effects 0.000 claims description 3
- 229930195711 D-Serine Natural products 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 101100281510 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-6 gene Proteins 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 8
- IMTUWVJPCQPJEE-IUCAKERBSA-N Met-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN IMTUWVJPCQPJEE-IUCAKERBSA-N 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 claims 1
- CZVQSYNVUHAILZ-UWVGGRQHSA-N His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 CZVQSYNVUHAILZ-UWVGGRQHSA-N 0.000 claims 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 claims 1
- 101100401106 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-7 gene Proteins 0.000 claims 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 1
- 108010040030 histidinoalanine Proteins 0.000 claims 1
- 108010073969 valyllysine Proteins 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 description 79
- 241000588724 Escherichia coli Species 0.000 description 44
- 241000191963 Staphylococcus epidermidis Species 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 19
- 235000004279 alanine Nutrition 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
- 238000010647 peptide synthesis reaction Methods 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 150000008575 L-amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000002802 antimicrobial activity assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920004688 Altek® Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- VHWBWHBJEXGPNM-UHFFFAOYSA-N N(2)-(2,4-dichlorophenyl)-N-(7-{[(2,4-dichlorophenyl)amino]sulfonyl}-1-oxo-1,2-dihydronaphthalen-2-yl)glycinamide Chemical compound ClC1=CC(Cl)=CC=C1NCC(=O)NC1C(=O)C2=CC(S(=O)(=O)NC=3C(=CC(Cl)=CC=3)Cl)=CC=C2C=C1 VHWBWHBJEXGPNM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229940021746 d- serine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37675489A | 1989-07-07 | 1989-07-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL94939A0 IL94939A0 (en) | 1991-06-10 |
| IL94939A true IL94939A (en) | 1996-12-05 |
Family
ID=23486335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9493990A IL94939A (en) | 1989-07-07 | 1990-07-02 | Transformed Analogs of Maginin Peptide and Their Use |
Country Status (16)
| Country | Link |
|---|---|
| EP (4) | EP0751149A3 (es) |
| JP (1) | JP2854970B2 (es) |
| CN (1) | CN1055480C (es) |
| AT (1) | ATE146188T1 (es) |
| AU (1) | AU650236B2 (es) |
| CA (1) | CA2020663C (es) |
| DE (1) | DE69029377T2 (es) |
| DK (1) | DK0437556T3 (es) |
| ES (1) | ES2095255T3 (es) |
| IE (1) | IE63842B1 (es) |
| IL (1) | IL94939A (es) |
| PH (4) | PH30054A (es) |
| PT (1) | PT94625B (es) |
| SG (1) | SG47913A1 (es) |
| WO (1) | WO1991000869A1 (es) |
| ZA (1) | ZA905203B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2854970B2 (ja) * | 1989-07-07 | 1999-02-10 | スクリップス クリニック アンド リサーチ ファウンデーション | マガイニンペプチドの置換アナログ |
| US5221664A (en) * | 1990-04-23 | 1993-06-22 | Magainin Pharmaaceuticals Inc. | Composition and treatment with biologically active peptides and toxic cations |
| AU648140B2 (en) * | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
| EP0590044A4 (en) * | 1991-06-12 | 1996-06-12 | Magainin Pharma | Composition and treatment with biologically active peptides having c-terminal substitutions |
| US5424290A (en) * | 1992-10-26 | 1995-06-13 | Magainin Pharmaceuticals Inc. | Biologically active peptides and uses therefor |
| US5773413A (en) * | 1993-06-04 | 1998-06-30 | Demeter Biotechnologies, Ltd. | Method of combating mammalian neoplasias, and lytic peptides therefor |
| US5561107A (en) * | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
| CN101928340A (zh) * | 2009-12-24 | 2010-12-29 | 深圳市圣西马生物技术有限公司 | 一组抗菌肽衍生物及其应用 |
| CN104710523B (zh) * | 2013-12-11 | 2017-12-29 | 华东理工大学 | 对铜绿假单胞菌具有抗菌性能的Magainin肽修饰物及其制备方法 |
| CA2989311A1 (en) * | 2015-07-02 | 2017-01-05 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides |
| EP3423075B1 (en) | 2016-02-29 | 2024-04-03 | Dana-Farber Cancer Institute, Inc. | Stapled intracellular-targeting antimicrobial peptides to treat infection |
| JP7305614B2 (ja) * | 2017-07-19 | 2023-07-10 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド |
| CN111892646B (zh) * | 2020-08-13 | 2023-05-02 | 中国人民解放军军事科学院军事医学研究院 | 抗菌肽衍生物及其在制备抗细菌感染药物中的应用 |
| CN112625092B (zh) * | 2021-01-13 | 2023-03-28 | 兰州大学 | 一种基于polybia-MPI的抗菌多肽化合物及其合成与应用 |
| CN114634553B (zh) * | 2022-04-27 | 2024-03-08 | 贵州医科大学 | 阳离子肽c9及其应用 |
| CN120081951B (zh) * | 2025-03-06 | 2025-09-30 | 辽宁波尔莱特农牧实业集团有限公司 | 一种抗菌肽Magainin 2-hEGF融合蛋白及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE106896T1 (de) * | 1987-03-04 | 1994-06-15 | Us Health | Neue synthetische bioaktive verbindungen und verfahren zur herstellung bioaktiver wirkungen. |
| US4810777A (en) * | 1987-03-04 | 1989-03-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antimicrobial compounds |
| JP2854970B2 (ja) * | 1989-07-07 | 1999-02-10 | スクリップス クリニック アンド リサーチ ファウンデーション | マガイニンペプチドの置換アナログ |
-
1990
- 1990-06-28 JP JP2509660A patent/JP2854970B2/ja not_active Expired - Fee Related
- 1990-06-28 SG SG1996005217A patent/SG47913A1/en unknown
- 1990-06-28 WO PCT/US1990/003675 patent/WO1991000869A1/en not_active Ceased
- 1990-06-28 DE DE69029377T patent/DE69029377T2/de not_active Expired - Fee Related
- 1990-06-28 AT AT90909538T patent/ATE146188T1/de not_active IP Right Cessation
- 1990-06-28 EP EP96201385A patent/EP0751149A3/en not_active Ceased
- 1990-06-28 AU AU59454/90A patent/AU650236B2/en not_active Ceased
- 1990-06-28 EP EP90909538A patent/EP0437556B1/en not_active Expired - Lifetime
- 1990-06-28 DK DK90909538.2T patent/DK0437556T3/da active
- 1990-06-28 ES ES90909538T patent/ES2095255T3/es not_active Expired - Lifetime
- 1990-06-28 EP EP96201384A patent/EP0751148A3/en not_active Ceased
- 1990-06-28 EP EP96201383A patent/EP0761684A3/en not_active Ceased
- 1990-07-02 IL IL9493990A patent/IL94939A/en active IP Right Grant
- 1990-07-03 ZA ZA905203A patent/ZA905203B/xx unknown
- 1990-07-06 IE IE247690A patent/IE63842B1/en not_active IP Right Cessation
- 1990-07-06 PT PT94625A patent/PT94625B/pt not_active IP Right Cessation
- 1990-07-06 CA CA002020663A patent/CA2020663C/en not_active Expired - Lifetime
- 1990-07-06 PH PH40802A patent/PH30054A/en unknown
- 1990-07-06 CN CN90106803A patent/CN1055480C/zh not_active Expired - Fee Related
-
1992
- 1992-12-21 PH PH45486A patent/PH30219A/en unknown
- 1992-12-21 PH PH45487A patent/PH30410A/en unknown
- 1992-12-21 PH PH45488A patent/PH30218A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU650236B2 (en) | 1994-06-16 |
| JP2854970B2 (ja) | 1999-02-10 |
| EP0437556A1 (en) | 1991-07-24 |
| DK0437556T3 (da) | 1996-12-30 |
| EP0437556B1 (en) | 1996-12-11 |
| AU5945490A (en) | 1991-02-06 |
| PT94625A (pt) | 1991-03-20 |
| EP0437556A4 (en) | 1992-05-20 |
| CN1049166A (zh) | 1991-02-13 |
| EP0751148A3 (en) | 1997-07-02 |
| WO1991000869A1 (en) | 1991-01-24 |
| EP0751149A2 (en) | 1997-01-02 |
| CA2020663A1 (en) | 1991-01-08 |
| DE69029377T2 (de) | 1997-06-19 |
| CN1055480C (zh) | 2000-08-16 |
| CA2020663C (en) | 1999-12-07 |
| EP0751148A2 (en) | 1997-01-02 |
| ATE146188T1 (de) | 1996-12-15 |
| SG47913A1 (en) | 1998-04-17 |
| EP0751149A3 (en) | 1997-07-02 |
| ZA905203B (en) | 1991-05-29 |
| PH30218A (en) | 1997-02-05 |
| JPH04506801A (ja) | 1992-11-26 |
| EP0761684A2 (en) | 1997-03-12 |
| ES2095255T3 (es) | 1997-02-16 |
| IE63842B1 (en) | 1995-06-14 |
| IL94939A0 (en) | 1991-06-10 |
| IE902476A1 (en) | 1991-02-13 |
| EP0761684A3 (en) | 1997-07-02 |
| PH30410A (en) | 1997-05-09 |
| DE69029377D1 (de) | 1997-01-23 |
| PH30054A (en) | 1996-11-08 |
| PT94625B (pt) | 1997-03-31 |
| PH30219A (en) | 1997-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5294605A (en) | Amphiphilic peptide compositions and analogues thereof | |
| US4962277A (en) | Deletion analogues of magainin peptides | |
| JP3266311B2 (ja) | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 | |
| EP0437556B1 (en) | Substitution analogues of magainin peptides | |
| EP1386928B1 (en) | A frog skin antibacterial peptide derivative | |
| EP2548883A2 (en) | Peptide compounds that can be used as antibacterial agents | |
| US5912231A (en) | Substitution analogues of magainin peptides | |
| WO1998016549A1 (en) | Antimicrobial peptide analogs of gramicidin s and compositions comprising them | |
| WO1989011290A1 (en) | Amphiphilic peptides and use thereof | |
| CN119350445B (zh) | 一种基于Tritrpticin的衍生抗菌肽及其合成方法和在抗菌方面的应用 | |
| CA2047317A1 (en) | Amphiphilic peptide compositions and analogues thereof | |
| US7723467B2 (en) | Antimicrobial compounds | |
| WO1991019512A1 (en) | Antimicrobial peptides | |
| JPH0656889A (ja) | 新規ペプチドおよび抗菌剤 | |
| WO1995016702A1 (en) | Peptide inhibitors of cxc intercrine molecules | |
| US4330465A (en) | Novel β-endorphin analogs | |
| CN120058864A (zh) | Peg化抗菌肽制备及其在细菌感染中的应用 | |
| CN115010788A (zh) | N-末端脂肪酸修饰的具有抗生物膜活性的低毒广谱抗菌肽类似物及其应用 | |
| JPH06199893A (ja) | 新規ペプチドおよび抗菌剤 | |
| JPH0656888A (ja) | 新規ペプチドおよび抗菌剤 | |
| JP2005532784A (ja) | 新規の抗菌ボリシンペプチド | |
| NO904846L (no) | Amfifile peptider og anvendelse derav. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |